Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLOOM: Zorifertinib or Osimertinib in EGFR+ NSCLC
NCT02228369Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2014
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of zorifertinib and osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by AstraZeneca. Primary endpoint: Safety and Tolerability. Started Nov 2014; status: completed.
02
Drugs
zorifertinibosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02228369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228369.